Antagonists with position 13 modification
US5093233A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 25, 1990 |
| Grant date | Mar 3, 1992 |
| Priority date | — |
| Expiry date | Apr 25, 2010 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is exemplified by parathyroid hormone (PTH), wherein Lys.sup.13 is substituted to increase the biological activity of the PTH analogues. Thus, there are disclosed peptides having the formulae: PA0 PTH(7-34)NH.sub.2 ; PA0 [Tyr.sup.34 ]PTH(7-34)NH.sub.2 ; PA0 [D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ; PA0 [Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ; PA0 [Nle.sup.8,18, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ; PA0 desamino[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(7-34)NH.sub.2 ; and, PA0 desamino[Nle.sup.8,18, D-Trp.sup.12, Tyr.sup.34 ]PTH(8-34)NH.sub.2 wherein Lys.sup.13 is modified in the epsilon-amino acid group by N,N-diisobutyl or 3-phenylpropanoyl.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.